Long-term pioglitazone treatment improves learning and attenuates pathological markers in a mouse model of alzheimer's disease

Journal of Alzheimer's Disease

Volumn 30, Issue 4, 2012, Pages 943-961

  Searcy, James L ^a,d   Phelps, Jeremiah T ^a,e   Pancani, Tristano ^a,f   Kadish, Inga ^b   Popovic, Jelena ^a   Anderson, Katie L ^a   Beckett, Tina L ^c   Murphy, Michael P ^c   Chen, Kuey Chu ^a   Blalock, Eric M ^a   Landfield, Philip W ^a   Porter, Nada M ^a   Thibault, Olivier ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

^e MICHIGAN STATE UNIVERSITY   (United States)

^f VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

3xTg AD; aging; hippocampus; long term potentiation; microarray analysis; pioglitazone; PPAR; T2DM

Indexed keywords

AMYLOID BETA PROTEIN; CHOLESTEROL; ESTROGEN; LIPID; PIOGLITAZONE; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AVOIDANCE BEHAVIOR; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ELECTROPHYSIOLOGY; FEMALE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HIPPOCAMPUS; HISTOPATHOLOGY; LIPID BLOOD LEVEL; LIVER; LONG TERM POTENTIATION; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SERODIAGNOSIS;

EID: 84862992514     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-111661     Document Type: Article

References (113)

1. Kochanek KD, Xu J, Murphy SL, Minino AM, Kung H-C (2011) Deaths: Preliminary data for 2009. Natl Vital Stat Rep 59-4, 1-68.
2. Hartmann T (2001) Cholesterol, A beta and Alzheimer's disease. Trends Neurosci 24, S45-S48.
3. Luchsinger JA(2008) Adiposity, hyperinsulinemia, diabetes and Alzheimer's disease: An epidemiological perspective. Eur J Pharmacol 585, 119-129.
4. Whitmer RA, Gustafson DR, Barrett-Connor E, Haan MN, Gunderson EP,YaffeK(2008) Central obesity and increased risk of dementia more than three decades later. Neurology 71, 1057-1064.
5. Biessels GJ, Deary IJ, Ryan CM (2008) Cognition and diabetes: A lifespan perspective. Lancet Neurol 7, 184-190.
6. Messier C, Gagnon M (2009) Cognitive decline associated with dementia and type 2 diabetes: The interplay of risk factors. Diabetologia 52, 2471-2474.
7. Abbatecola AM, Lattanzio F, Molinari AM, CioffiM,Mansi L, Rambaldi P, DiCioccio L, Cacciapuoti F, Canonico R, Paolisso G (2010) Rosiglitazone and cognitive stability in older individuals with type 2 diabetes and mild cognitive impairment. Diabetes Care 33, 1706-1711.
8. Risner ME, SaundersAM,Altman JF, Ormandy GC, Craft S, Foley IM, Zvartau-Hind ME, HosfordDA, RosesAD(2006) Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J 6, 246-254.
9. Ryan CM, Freed MI, Rood JA, Cobitz AR,Waterhouse BR, Strachan MW (2006) Improving metabolic control leads to better working memory in adults with type 2 diabetes. Diabetes Care 29, 345-351.
10. Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana S, Fishel MA, Kulstad JJ, Green PS, Cook DG, Kahn SE, Keeling ML, Craft S (2005) Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: A preliminary study. Am J Geriatr Psychiatry 13, 950-958.
11. Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T (2011) Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging 32, 1626-1633.
12. Berger JP, Akiyama TE, Meinke PT (2005) PPARs: Therapeutic targets for metabolic disease. Trends Pharmacol Sci 26, 244-251.
13. Francis GA, Fayard E, Picard F, Auwerx J (2003) Nuclear receptors and the control of metabolism. Annu Rev Physiol 65, 261-311.
14. de Souza CJ, Eckhardt M, Gagen K, Dong M, Chen W, Laurent D, Burkey BF (2001) Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes 50, 1863-1871.
15. Bogacka I, Xie H, Bray GA, Smith SR (2004) The effect of pioglitazone on peroxisome proliferator-activated receptorgamma target genes related to lipid storage in vivo. Diabetes Care 27, 1660-1667.
16. Esposito K, Ciotola M, Merante D, Giugliano D (2006) Rosiglitazone cools down inflammation in the metabolic syndrome. Arterioscler Thromb Vasc Biol 26, 1413-1414.
17. Wang TD, Chen WJ, Cheng WC, Lin JW, Chen MF, Lee YT (2006) Relation of improvement in endothelium-dependent flow-mediated vasodilation after rosiglitazone to changes in asymmetric dimethylarginine, endothelin-1, and C-reactive protein in nondiabetic patients with the metabolic syndrome. Am J Cardiol 98, 1057-1062.
18. Heneka MT, Sastre M, Dumitrescu-Ozimek L, Hanke A, Dewachter I, Kuiperi C, O'Banion K, Klockgether T, Van Leuven F, Landreth GE (2005) Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain 128, 1442-1453.
19. Feinstein DL (2003) Therapeutic potential of peroxisome proliferator-activated receptor agonists for neurological disease. Diabetes Technol Ther 5, 67-73.
20. Lacombe P, Mathews PM, Schmidt SD, Breidert T, Heneka MT, Landreth GE, Feinstein DL, Galea E (2004) Effect of anti-inflammatory agents on transforming growth factor beta over-expressing mouse brains: A model revised. J Neuroinflammation 1, 11.
21. Landreth GE, HenekaMT(2001) Anti-inflammatory actions of peroxisome proliferator-activated receptor gamma agonists in Alzheimer's disease. Neurobiol Aging 22, 937-944.
22. Nicolakakis N, Aboulkassim T, Ongali B, Lecrux C, Fernandes P, Rosa-Neto P, Tong XK, Hamel E (2008) Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist. J Neurosci 28, 9287-9296.
23. To AW, Ribe EM, Chuang TT, Schroeder JE, Lovestone S (2011) The epsilon3 and epsilon4 alleles of human APOE differentially affect tau phosphorylation in hyperinsulinemic and pioglitazone treated mice. PLoS ONE 6, e16991.
24. Escribano L, Simon AM, Gimeno E, Cuadrado-Tejedor M, Lopez de Maturana R, Garcia-Osta A, Ricobaraza A, Perez-Mediavilla A, Del Rio J, FrechillaD(2010) Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: Mechanisms involving a reduced amyloid and tau pathology. Neuropsychopharmacology 35, 1593-1604.
25. Escribano L, Simon AM, Perez-Mediavilla A, Salazar-Colocho P, Del Rio J, Frechilla D (2009) Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer's disease mouse model. Biochem Biophys Res Commun 379, 406-410.
26. Garcia-Bueno B, Madrigal JL, Lizasoain I, Moro MA, Lorenzo P, Leza JC (2005) Peroxisome proliferatoractivated receptor gamma activation decreases neuroinflammation in brain after stress in rats. Biol Psychiatry 57, 885-894.
27. Pedersen WA, Flynn ER (2004) Insulin resistance contributes to aberrant stress responses in the Tg2576 mouse model of Alzheimer's disease. Neurobiol Dis 17, 500-506.
28. PedersenWA, McMillan PJ, Kulstad JJ, Leverenz JB, Craft S, Haynatzki GR (2006) Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp Neurol 199, 265-273.
29. Yan Q, Zhang J, Liu H, Babu-Khan S, Vassar R, Biere AL, Citron M, Landreth G (2003) Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci 23, 7504-7509.
30. Rodriguez-Rivera J, Denner L, Dineley KT (2011) Rosiglitazone reversal of Tg2576 cognitive deficits is independent of peripheral gluco-regulatory status. Behav Brain Res 216, 255-261.
31. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: Intracellular Abeta and synaptic dysfunction. Neuron 39, 409-421.
32. Brunmair B, Staniek K, Lehner Z, Dey D, Bolten CW, Stadlbauer K, Luger A, Furnsinn C (2011) Lipophilicity as a determinant of thiazolidinedione action in vitro: Findings from BLX-1002, a novel compound without affinity to PPARs. Am J Physiol Cell Physiol 300, C1386-C1392.
33. Munoz C, Grossman SP (1981) Spatial discrimination, reversal and active or passive avoidance learning in rats with KA-induced neuronal depletions in dorsal hippocampus. Brain Res Bull 6, 399-406.
34. Phillips M, Boman E, Osterman H, Willhite D, Laska M (2011) Olfactory and visuospatial learning and memory performance in two strains of Alzheimer's disease model mice-a longitudinal study. PLoS ONE 6, e19567.
35. Wesson DW, Levy E, Nixon RA, Wilson DA (2010) Olfactory dysfunction correlates with amyloid-beta burden in an Alzheimer's disease mouse model. J Neurosci 30, 505-514.
36. Sterniczuk R, AntleMC,Laferla FM, DyckRH(2010) Characterization of the 3xTg-AD mouse model of Alzheimer's disease: Part 2. Behavioral and cognitive changes. Brain Res 1348, 149-155.
37. Alexandrov PN, Pogue A, Bhattacharjee S, Lukiw WJ (2011) Retinal amyloid peptides and complement factor H in transgenic models of Alzheimer's disease. Neuroreport 22, 623-627.
38. Rowe WB, Blalock EM, Chen KC, Kadish I, Wang D, Barrett JE, Thibault O, Porter NM, Rose GM, Landfield PW (2007) Hippocampal expression analyses reveal selective association of immediate-early, neuroenergetic, and myelinogenic pathways with cognitive impairment in aged rats. J Neurosci 27, 3098-3110.
39. Kadish I, Thibault O, Blalock EM, Chen KC, Gant JC, Porter NM, Landfield PW (2009) Hippocampal and cognitive aging across the lifespan: A bioenergetic shift precedes and increased cholesterol trafficking parallels memory impairment. J Neurosci 29, 1805-1816.
40. Blalock EM, Geddes JW, Chen KC, Porter NM,Markesbery WR, Landfield PW (2004) Incipient Alzheimer's disease: Microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci U S A 101, 2173-2178.
41. Blalock EM, Chen KC, Sharrow K, Herman JP, Porter NM, Foster TC, Landfield PW (2003) Gene microarrays in hippocampal aging: Statistical profiling identifies novel processes correlated with cognitive impairment. J Neurosci 23, 3807-3819.
42. Bolstad BM, Collin F, Brettschneider J, Simpson K, Cope L, Irizarry R, Speed TP (2005) Quality assessment of affymetrix GeneChip data. In: Bioinformatics and Computational Biology Solutions Using R and Bioconductor, Gentleman R, Carey V, HuberW, Irizarry R, Dudoit S, Eds. Springer, pp. 33-47.
43. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JY, Zhang J (2004) Bioconductor: Open software development for computational biology and bioinformatics. Genome Biol 5, R80.
44. Wu Z, Irizarry RA, Gentleman R, Martinez-Murillo F, Spencer F (2004) A model-based background adjustment for oligonucleotide expression arrays. JASA 99, 909-917.
45. Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, Braisted J, Klapa M, Currier T, Thiagarajan M, Sturn A, Snuffin M, Rezantsev A, Popov D, Ryltsov A, Kostukovich E, Borisovsky I, Liu Z, Vinsavich A, Trush V, Quackenbush J (2003) TM4: A free, open-source system for microarray data management and analysis. BioTechniques 34, 374-378.
46. Huang daW, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4, 44-57.
47. BarrettT,Troup DB,Wilhite SE, Ledoux P, RudnevD,Evangelista C, Kim IF, Soboleva A, Tomashevsky M, Marshall KA, Phillippy KH, Sherman PM, Muertter RN, Edgar R (2009) NCBI GEO: Archive for high-throughput functional genomic data. Nucleic Acids Res 37, D885-D890.
48. van Groen T, Miettinen P, Kadish I (2011) Transgenic AD model mice, effects of potential anti-AD treatments on inflammation, and pathology. J Alzheimers Dis 24, 301-313.
49. Pop V, Head E, Berchtold NC, Glabe CG, Studzinski CM, Weidner AM, Murphy MP, Cotman CW (2012) Abeta aggregation profiles and shifts in APP processing favor amyloidogenesis in canines. Neurobiol Aging 33, 108-120.
50. Beckett TL, Niedowicz DM, Studzinski CM, Weidner AM, Webb RL, Holler CJ, Ahmed RR, LeVine H 3rd, Murphy MP (2010) Effects of nonsteroidal anti-inflammatory drugs on amyloid-beta pathology in mouse skeletal muscle. Neurobiol Dis 39, 449-456.
51. Gant JC, Sama MM, Landfield PW, Thibault O (2006) Early and simultaneous emergence of multiple hippocampal biomarkers of aging is mediated by Ca2+-induced Ca2+release. J Neurosci 26, 3482-3490.
52. Gant JC, Thibault O (2009) Action potential throughput in aged rat hippocampal neurons: Regulation by selective forms of hyperpolarization. Neurobiol Aging 30, 2053-2064.
53. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE (2007) Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials. JAMA 298, 1180-1188.
54. Henriksen K, Byrjalsen I, Nielsen RH, Madsen AN, Larsen LK, Christiansen C, Beck-Nielsen H, Karsdal MA (2009) A comparison of glycemic control, water retention, and musculoskeletal effects of balaglitazone and pioglitazone in diet-induced obese rats. Eur J Pharmacol 616, 340-345.
55. Camacho IE, Serneels L, Spittaels K, Merchiers P, Dominguez D, De Strooper B (2004) Peroxisomeproliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide. J Neurosci 24, 10908-10917.
56. LaFerla FM, Green KN, Oddo S (2007) Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci 8, 499-509.
57. d'Abramo C, Ricciarelli R, Pronzato MA, Davies P (2006) Troglitazone, a peroxisome proliferator-activated receptor-gamma agonist, decreases tau phosphorylation in CHOtau4R cells. J Neurochem 98, 1068-1077.
58. Blalock EM, Phelps JT, Pancani T, Searcy JL, Anderson KL, Gant JC, Popovic J, Avdiushko MG, Cohen DA, Chen KC, Porter NM, Thibault O (2010) Effects of long-term pioglitazone treatment on peripheral and central markers of aging. PLoS ONE 5, e10405.
59. Gant JC, Thibault O (2008) Action potential throughput in aged rat hippocampal neurons: Regulation by selective forms of hyperpolarization. Neurobiol Aging 30, 2053-2064.
60. Thibault O, Hadley R, Landfield PW (2001) Elevated postsynaptic[Ca2+]i and L-type calcium channel activity in aged hippocampal neurons: Relationship to impaired synaptic plasticity. J Neurosci 21, 9744-9756.
61. Kim HB, Kumar A,Wang L, Liu GH, Keller SR, Lawrence JC Jr, Finck BN, Harris TE (2010) Lipin 1 represses NFATc4 transcriptional activity in adipocytes to inhibit secretion of inflammatory factors. Mol Cell Biol 30, 3126-3139.
62. Yau JL, Noble J, Seckl JR (2011) 11beta-hydroxysteroid dehydrogenase type 1 deficiency prevents memory deficits with aging by switching from glucocorticoid receptor to mineralocorticoid receptor-mediated cognitive control. J Neurosci 31, 4188-4193.
63. Seckl JR, Walker BR (2004) 11beta-hydroxysteroid dehydrogenase type 1 as a modulator of glucocorticoid action: From metabolism to memory. Trends Endocrinol Metab 15, 418-424.
64. Tong G, Takahashi H, Tu S, Shin Y, Talantova M, Zago W, Xia P, Nie Z, Goetz T, Zhang D, Lipton SA, Nakanishi N (2008) Modulation ofNMDAreceptor properties and synaptic transmission by theNR3Asubunit in mouse hippocampal and cerebrocortical neurons. J Neurophysiol 99, 122-132.
65. Schmid SM, HollmannM(2008) To gate or not to gate: Are the delta subunits in the glutamate receptor family functional ion channels? Mol Neurobiol 37, 126-141.
66. Chou JL, Shenoy DV, Thomas N, Choudhary PK, Laferla FM, Goodman SR, Breen GA (2011) Early dysregulation of the mitochondrial proteome in a mouse model of Alzheimer's disease. J Proteomics 74, 466-479.
67. Martin B, Brenneman R, Becker KG, Gucek M, Cole RN, Maudsley S (2008) iTRAQ analysis of complex proteomealterations in 3×TgAD Alzheimer's mice: Understanding the interface between physiology and disease. PLoS ONE 3, e2750.
68. Costello DA, O'Leary DM, Herron CE (2005) Agonists of peroxisome proliferator-activated receptor-gamma attenuate the Abeta-mediated impairment of LTP in the hippocampus in vitro. Neuropharmacology 49, 359-366.
69. Loane DJ, Deighan BF, Clarke RM, Griffin RJ, Lynch AM, Lynch MA (2009) Interleukin-4 mediates the neuroprotective effects of rosiglitazone in the aged brain. Neurobiol Aging 30, 920-931.
70. Baudry M, Lynch G (2001) Remembrance of arguments past: How well is the glutamate receptor hypothesis of LTP holding up after 20 years? Neurobiol Learn Mem 76, 284-297.
71. Woltjer RL, Duerson K, Fullmer JM, Mookherjee P, Ryan AM,Montine TJ, Kaye JA, Quinn JF, Silbert L, Erten-Lyons D, Leverenz JB, Bird TD, Pow DV, Tanaka K, Watson GS, Cook DG (2010) Aberrant detergent-insoluble excitatory amino acid transporter 2 accumulates in Alzheimer disease. J Neuropathol Exp Neurol 69, 667-676.
72. Lipton SA (2007) Pathologically activated therapeutics for neuroprotection. Nat Rev Neurosci 8, 803-808.
73. Lipton SA (2004) Failures and successes of NMDA receptor antagonists: Molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRx 1, 101-110.
74. McShane R, Areosa Sastre A, Minakaran N (2006) Memantine for dementia. Cochrane Database Syst Rev CD003154.
75. ReisbergB, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ (2006)A24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol 63, 49-54.
76. Frankiewicz T, Pilc A, Parsons CG (2000) Differential effects of NMDA-receptor antagonists on long-term potentiation and hypoxic/hypoglycaemic excitotoxicity in hippocampal slices. Neuropharmacology 39, 631-642.
77. Pieta Dias C, Martins de Lima MN, Presti-Torres J, Dornelles A, Garcia VA, Siciliani Scalco F, Rewsaat Guimaraes M, Constantino L, Budni P, Dal-Pizzol F, SchroderN(2007) Memantine reduces oxidative damage and enhances longterm recognition memory in aged rats. Neuroscience 146, 1719-1725.
78. Martinez-Coria H, Green KN, Billings LM, Kitazawa M, Albrecht M, Rammes G, Parsons CG, Gupta S, Banerjee P, LaFerla FM (2010) Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice. Am J Pathol 176, 870-880.
79. Burke SN, Maurer AP, Yang Z, Navratilova Z, Barnes CA (2008) Glutamate receptor-mediated restoration of experience-dependent place field expansion plasticity in aged rats. Behav Neurosci 122, 535-548.
80. Pancani T, Phelps JT, Searcy JL, Kilgore MW, Chen KC, Porter NM, Thibault O (2009) Distinct modulation of voltage-gated and ligand-gated Ca2+ currents by PPAR-gamma agonists in cultured hippocampal neurons. J Neurochem 109, 1800-1811.
81. Machado-Vieira R, Ibrahim L, Henter ID, Zarate CA Jr (2012) Novel glutamatergic agents for major depressive disorder and bipolar disorder. Pharmacol Biochem Behav 100, 678-687.
82. Kemp DE, Ismail-Beigi F, Ganocy SJ, Conroy C, Gao K, Obral S, Fein E, Findling RL, Calabrese JR (2012) Use of insulin sensitizers for the treatment of major depressive disorder: A pilot study of pioglitazone for major depression accompanied by abdominal obesity. J Affect Disord 136, 1164-1173.
83. DanyszW, Parsons CG (2003) TheNMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: Preclinical evidence. Int J Geriatr Psychiatry 18, S23-S32.
84. Abdallah DM (2010) Anticonvulsant potential of the peroxisome proliferator-activated receptor gamma agonist pioglitazone in pentylenetetrazole-induced acute seizures and kindling in mice. Brain Res 1351, 246-253.
85. Okada K, Yamashita U, Tsuji S (2006) Ameliorative effect of pioglitazone on seizure responses in genetically epilepsysusceptible EL mice. Brain Res 1102, 175-178.
86. Lewis AS, Vaidya SP, Blaiss CA, Liu Z, Stoub TR, Brager DH, Chen X, Bender RA, Estep CM, Popov AB, Kang CE, Van Veldhoven PP, Bayliss DA, Nicholson DA, Powell CM, Johnston D, Chetkovich DM (2011) Deletion of the hyperpolarization-activated cyclic nucleotide-gated channel auxiliary subunit TRIP8b impairs hippocampal Ih localization and function and promotes antidepressant behavior in mice. J Neurosci 31, 7424-7440.
87. Nolan MF, Malleret G, Dudman JT, Buhl DL, Santoro B, Gibbs E, Vronskaya S, Buzsaki G, Siegelbaum SA, Kandel ER, Morozov A (2004) A behavioral role for dendritic integration: HCN1 channels constrain spatial memory and plasticity at inputs to distal dendrites of CA1 pyramidal neurons. Cell 119, 719-732.
88. Disterhoft JF, Oh MM (2007) Alterations in intrinsic neuronal excitability during normal aging. Aging Cell 6, 327-336.
89. Stutzmann GE, Smith I, Caccamo A, Oddo S, Laferla FM, Parker I (2006) Enhanced ryanodine receptor recruitment contributes to Ca2+ disruptions in young, adult, and aged Alzheimer's disease mice. J Neurosci 26, 5180-5189.
90. Arsenault D, Julien C, Tremblay C, Calon F (2011) DHA improves cognition and prevents dysfunction of entorhinal cortex neurons in 3xTg-AD mice. PLoS ONE 6, e17397.
91. Minkeviciene R, Rheims S, Dobszay MB, Zilberter M, Hartikainen J, Fulop L, Penke B, Zilberter Y, Harkany T, Pitkanen A,TanilaH(2009) Amyloid beta-induced neuronal hyperexcitability triggers progressive epilepsy. J Neurosci 29, 3453-3462.
92. Palop JJ, Chin J, Roberson ED,Wang J, ThwinMT, Bien-Ly N, Yoo J, Ho KO, Yu GQ, Kreitzer A, Finkbeiner S, Noebels JL, Mucke L (2007) Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 55, 697-711.
93. Sparks DL (1997) Coronary artery disease, hypertension, ApoE, and cholesterol: A link to Alzheimer's disease? Ann N Y Acad Sci 826, 128-146.
94. Sparks DL (2008) The early and ongoing experience with the cholesterol-fed rabbit as amodel of Alzheimer's disease: The old, the newand the pilot. J Alzheimers Dis 15, 641-656.
95. Schreurs BG (2010) The effects of cholesterol on learning and memory. Neurosci Biobehav Rev 34, 1366-1379.
96. Mielke JG, Nicolitch K, Avellaneda V, Earlam K, Ahuja T, Mealing G, Messier C (2006) Longitudinal study of the effects of a high-fat diet on glucose regulation, hippocampal function, and cerebral insulin sensitivity in C57BL/6 mice. Behav Brain Res 175, 374-382.
97. Petanceska SS, DeRosa S, Sharma A, Diaz N, Duff K, Tint SG, Refolo LM, PappollaM(2003) Changes in apolipoprotein E expression in response to dietary and pharmacological modulation of cholesterol. J Mol Neurosci 20, 395-406.
98. Abdul HM, Sama MA, Furman JL, Mathis DM, Beckett TL, Weidner AM, Patel ES, Baig I, Murphy MP, LeVine H 3rd, Kraner SD, Norris CM (2009) Cognitive decline in Alzheimer's disease is associated with selective changes in calcineurin/NFAT signaling. J Neurosci 29, 12957-12969.
99. Parvathy S, Davies P, Haroutunian V, Purohit DP, Davis KL, Mohs RC, Park H, Moran TM, Chan JY, Buxbaum JD (2001) Correlation between Abetax-40-, Abetax-42-, and Abetax-43-containing amyloid plaques and cognitive decline. Arch Neurol 58, 2025-2032.
100. Westerman MA, Cooper-Blacketer D, Mariash A, Kotilinek L, Kawarabayashi T, Younkin LH, Carlson GA, Younkin SG, Ashe KH (2002) The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 22, 1858-1867.
101. Howlett DR, Richardson JC, Austin A, Parsons AA, Bate ST, Davies DC, Gonzalez MI (2004) Cognitive correlates of Abeta deposition in male and female mice bearing amyloid precursor protein and presenilin-1 mutant transgenes. Brain Res 1017, 130-136.
102. Allahtavakoli M, Shabanzadeh A, Roohbakhsh A, Pourshanazari A (2007) Combination therapy of rosiglitazone, a peroxisome proliferator-activated receptor-gamma ligand, and NMDA receptor antagonist (MK-801) on experimental embolic stroke in rats. Basic Clin Pharmacol Toxicol 101, 309-314.
103. Yi KD, Chung J, Pang P, Simpkins JW (2005) Role of protein phosphatases in estrogen-mediated neuroprotection. J Neurosci 25, 7191-7198.
104. Brewer LD, Dowling AL, Curran-Rauhut MA, Landfield PW, Porter NM, Blalock EM (2009) Estradiol reverses a calcium-related biomarker of brain aging in female rats. J Neurosci 29, 6058-6067.
105. Foster TC (2012) Role of estrogen receptor alpha and beta expression and signaling on cognitive function during aging. Hippocampus 22, 656-669.
106. Kumar A, Foster TC (2002) 17beta-estradiol benzoate decreases the AHP amplitude in CA1 pyramidal neurons. J Neurophysiol 88, 621-626.
107. Wu TW, Wang JM, Chen S, Brinton RD (2005) 17Betaestradiol induced Ca2+ influx via L-type calcium channels activates the Src/ERK/cyclic-AMP response element binding protein signal pathway and BCL-2 expression in rat hippocampal neurons: A potential initiation mechanism for estrogen-induced neuroprotection. Neuroscience 135, 59-72.
108. Brinton RD (2008) The healthy cell bias of estrogen action: Mitochondrial bioenergetics and neurological implications. Trends Neurosci 31, 529-537.
109. Foy MR, Baudry M, Diaz Brinton R, Thompson RF (2008) Estrogen and hippocampal plasticity in rodent models. J Alzheimers Dis 15, 589-603.
110. Simpkins JW, SinghM(2008) More than a decade of estrogen neuroprotection. Alzheimers Dement 4, S131-S136.
111. Carroll JC, Rosario ER, Chang L, Stanczyk FZ, Oddo S, LaFerla FM, Pike CJ (2007) Progesterone and estrogen regulate Alzheimer-like neuropathology in female 3xTg-AD mice. J Neurosci 27, 13357-13365.
112. Zhao L, Yao J, Mao Z, Chen S, Wang Y, Brinton RD (2011) 17beta-Estradiol regulates insulin-degrading enzyme expression via an ERbeta/PI3-K pathway in hippocampus: Relevance to Alzheimer's prevention. Neurobiol Aging 32, 1949-1963.
113. Sastre M, Dewachter I, Rossner S, Bogdanovic N, Rosen E, Borghgraef P, Evert BO, Dumitrescu-Ozimek L, Thal DR, Landreth G,Walter J, Klockgether T, van Leuven F, Heneka MT (2006) Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc Natl Acad Sci U S A 103, 443-448.